Myeloproliferative Neoplasms

Jeanne M. Palmer, MD, discusses total symptom scores in patients with myelofibrosis with thrombocytopenia.

Low platelet counts were associated with a greater severity of disease-related symptoms compared with low hemoglobin in patients with myelofibrosis, according to findings from a retrospective analysis of the phase 3 PERSIST-1 and PAC203 trials.

Momelotinib elicited durable symptom, transfusion independence, and splenic responses through 48 weeks of treatment in patients with myelofibrosis who have anemia and previously received a JAK inhibitor.

The combination of selinexor and ruxolitinib significantly reduced spleen volume and total symptom score while achieving hemoglobin stabilization in an open-label dose-escalation/dose-expansion, phase 1 study of patients with treatment-naïve myelofibrosis.

Olverembatinib was found to uphold clinical benefit and continued to have an acceptable safety profile in patients with BCR-ABL1 T315I-mutant chronic myeloid leukemia -chronic phase or -acute phase that is resistant to TKIs.

The European Medicines Agency has accepted a marketing authorization application for momelotinib as a treatment for patients with myelofibrosis.

Gary J. Schiller, MD, discusses the benefits and challenges associated with JAK-directed therapies in the treatment of patients with myelofibrosis.

John O. Mascarenhas, MD, discusses current advancement in the treatment landscape of myelofibrosis.

John Mascarenhas, MD, discusses the shifts from monotherapy to combination therapies in the evolving field of myelofibrosis care.

Raajit K. Rampal, MD, PhD, discusses the future research of CDK4/6 inhibitors in myeloproliferative neoplasms.

Raajit K. Rampal, MD, PhD, discusses the investigation of pelabresib with or without ruxolitinib in patients with myelofibrosis.

Gary J. Schiller, MD, discusses several areas of unmet need in myelofibrosis, and how to potentially address these challenges.

Ahead of the 40th Annual Chemotherapy Foundation Symposium, Pinkal Desai, MD, addresses the evolving role of targeted therapies in MDS and how clinicians can characterize MDS risk.

Mikkael A. Sekeres, MD, MS, discussed the changes to the classifications of MDS, the evolution of targeted therapies for patients with acute myeloid leukemia, and approaches for patients with bone marrow failure syndromes.

The European Commission has granted an orphan drug designation to selinexor for the treatment of patients with myelofibrosis.

Luspatercept generated a statistically significant improvement in red blood cell transfusion independence with concurrent hemoglobin increase vs epoetin alfa in patients with very low–, low-, or intermediate-risk myelodysplastic syndromes who require RBC transfusions, meeting the primary end point of the phase 3 COMMANDS trial.

Andrew Kuykendall, MD, discusses treatment considerations with ruxolitinib in myelofibrosis.

Haris Ali, MD, discusses a phase 1 dose-escalation trial investigating the administration of selinexor in combination with ruxolitinib for patients with treatment-naïve myelofibrosis.

Luspatercept produced favorable safety and long-term efficacy in patients with untreated lower-risk myelodysplastic syndromes, irrespective of subtype.

Patients with polycythemia vera, a myeloproliferative neoplasm associated with JAK2 mutations and overproduction of red blood cells, often require regular therapeutic phlebotomies to avoid thrombosis.

Momelotinib induced superior 24-week overall survival rates compared with danazol in thrombocytopenic, symptomatic, and anemic patients with myelofibrosis.

Haris Ali, MD, discusses the investigation of ruxolitinib and navitoclax combination therapy in myelofibrosis.

Treatment with GB2064 monotherapy for at least 6 months led to a reduction in collagen fibrosis of the bone marrow of at least 1 grade in 4 of 5 evaluable patients with myelofibrosis, according to topline findings from a planned intermediate assessment of the phase 2a MYLOX-1 trial.

Treatment with rusfertide generated sustained hematocrit control at levels below 45% in patients with polycythemia vera, leading to a reduced need for repeated phlebotomy and eliminating this need in some patients, according to findings from 2 phase 2 clinical trials.

Andrew Kuykendall, MD, discusses the evolution of prognostication factors in primary and secondary myelofibrosis.

John O. Mascarenhas, MD, discusses the investigation of pelabresib in myelofibrosis.

Azacitidine plus venetoclax showed encouraging activity in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

Emavusertib elicited antitumor activity when given as a monotherapy in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome that harbored a spliceosome or FLT3 mutation.

A panel of hematology cancer experts discuss the current treatment landscape and novel emerging therapies for patients with myelofibrosis.